|
|
 |
|
Viewing report
|
|
|
|
Autoimmune Market Outlook to 2012
Business Insights, July 2007, Pages: 216
Autoimmune related disorders continue to maintain prominence within the global disease burden, having achieved a worldwide market growth of 9.4% over the 2002-06 period. However, the inherent threat of generic competition and novel product launches are forecast to transform the dynamics of the autoimmune market over the next 5 years. The autoimmune pipeline represents a key opportunity for drug development companies, with the potential for success largely attributable to substantial unmet demand, a significant patient population and the medical proclivity for long term treatments.
In consequence, the effective exploitation of market potential is becoming increasingly crucial, and hinges upon drug developments that accurately reflect the shifting demographics of autoimmune disorders and unmet patient needs. Autoimmune Market Outlook to 2012 is a new report published, examining how the competitive dynamics of major pharma companies will influence the market positions of products and shape the direction of future global autoimmunology. Market trends and leading brands of treatment are extensively profiled, while the most commercially promising R&D therapies are investigated and assessed to discover their sales potential.
This report will also provide a comprehensive epidemiological analysis of the major indications and detailed product sales forecasts. Use this report to identify opportunities in the autoimmune pipeline, assess the dynamics of leading competitors and evaluate the impact of key trends across the global market.
Some key findings from this report
- The global autoimmune market is forecast to expand at a CAGR of 3.7% over the period 2006-12, as weak performances from generics dominated classes weigh down the development of innovative medicines in the arthritis and psoriasis market segments.
- 68.9% or $19,241m of the global market in 2006 was held by the ten leading companies, despite a slowdown in growth attributed to strong generic competition, lack of innovation and mature product portfolios.
- Original brand sales dominate the autoimmune market, accounting for 62.7% or $17.5bn of the market in 2006, largely due to labelling extensions across original branded products.
- The uptake of biologics remains slow, despite established clinical efficacy profiles due to high price points associated with their use. In addition, a weak regulatory procedure related to their approval has further hampered a strong hold on the market.
- The autoimmune market is forecast to offer declining returns, with future growth being driven by a small number of blockbuster products and the re-uptake of COX-II inhibitors.
Top five reasons to order your copy today
- Quantify patient potential, assess treatment trends and sales patterns across the major and emerging markets, in addition to the 10 leading companies within the global autoimmune market.
- Discover which autoimmune drug classes will provide the greatest franchise growth potential and identify the growth drivers of major treatment classes including immunosuppressants, antirheumatic agents, COX-II inhibitors, NSAIDs and corticosteroids.
- Compare and evaluate the franchises of top pharmaceutical marketers across the global autoimmune market, and evaluate how market share will change over the next 6 years for leading companies including Amgen, J&J, Novartis and Pfizer.
- Gain up-to-date competitive intelligence across the global autoimmune market and understand how the major issues are affecting key pharmaceutical marketers and product development.
- Forecast autoimmune sales to 2012 for currently marketed major products and key pipeline products.
Key issues examined in this report
- Resilience of biologics. Biologic compounds with indications in auto-immune disorders have remained prominent in R&D endeavours, despite experiencing a slow uptake attributed to high price points and weak regulatory procedures.
- Threat of immunosuppressants. Astellas’ Prograf and Roche’s Cellcept may pose a threat over the forecast period to established autoimmune agents such as Remicade, Enbrel and Humira, after seeking approval for rheumatoid arthritis and lupus nephritis.
- Reinvigoration of COX-II sales. The global market for COX-II inhibitors witnessed a damaging 66.3% ($5.0bn) drop in sales for 2005 due to the removal of blockbuster products, however modest growth of 6.3% over 2005-06 suggests confidence is returning.
- Aggressive marketing strategies of arthritis drugs. Several leading pharma companies including Humira and Abbot have expanded their currently marketed arthritis offering to include indications such as juvenile rheumatoid arthritis, psoriatic arthritis, psoriasis and Crohn’s disease.
Your questions answered
- What are the market size forecasts, growth rates and major growth drivers within the global market over the period 2006-2012?
- How have recent launches from companies such as Novartis and BMS performed?
- Which companies are best positioned to succeed and what will the competitive landscape look like over the period 2006-12?
- What are the most exciting compounds currently in development for autoimmune-related disorders, and what is the forecast market potential of these products?
- How significant is the threat of generics to the overall performance of the global autoimmune market?
- What are the current trends within the major autoimmune drug classes across the seven major markets?
Product samples
Pipeline Analysis Sample
Customers who bought this item also bought
Autoimmune/Inflammatory Disease: Competitive Strategies - Competitive Analysis, Profiles, and Portfolio Strategies of the Top Autoimmune/Inflammatory Therapeutic Manufacturers in the US (2001 Edition)
Autoimmune and Inflammation - Autoimmune Diseases Drug Pipeline Report
Biotech in Autoimmune and Inflammatory Disease 2006, 2nd Edition
The CNS Market Outlook to 2010
European Autoimmune Diseases Therapeutics Markets
Orphan Drugs Pipeline Analysis: Wider Incentives Encourage Orphan Drug R&D
Autoimmune/Inflammatory Disease Drug Licensing Opportunities: Analysis, Rating and Ranking - A Worldwide Study
Strategic Analysis of the Autoimmune Disease Diagnostics Market in Europe
|
|
|
|
